GSK250117C00055000 Option on GlaxoSmithKline PLC ADR

GSK Stock  USD 36.38  1.32  3.50%   
GlaxoSmithKline PLC's latest option contracts expiring on May 16th 2025 are carrying combined implied volatility of 0.36 with a put-to-call open interest ratio of 0.22 over 42 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on May 16th 2025. The total put volume is at 605, with calls trading at the volume of 668. This yields a 0.91 put-to-call volume ratio.

Open Interest Against May 16th 2025 Option Contracts

The chart above shows GlaxoSmithKline PLC's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. GlaxoSmithKline PLC's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for GlaxoSmithKline PLC's option, there is no secondary market available for investors to trade.

GlaxoSmithKline PLC Maximum Pain Price Across 2025-05-16 Option Contracts

GlaxoSmithKline PLC's max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.

In The Money vs. Out of Money Option Contracts on GlaxoSmithKline PLC

Analyzing GlaxoSmithKline PLC's in-the-money options over time can help investors to take a profitable long position in GlaxoSmithKline PLC regardless of its overall volatility. This is especially true when GlaxoSmithKline PLC's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money GlaxoSmithKline PLC's options could be used as guardians of the underlying stock as they move almost dollar for dollar with GlaxoSmithKline PLC's stock while costing only a fraction of its price.

GlaxoSmithKline PLC ADR In The Money Call Balance

When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying GlaxoSmithKline PLC's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on GlaxoSmithKline PLC ADR are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.

GlaxoSmithKline Current Options Market Mood

GlaxoSmithKline PLC's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps GlaxoSmithKline Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.

Put-to-Call Open Interest

Put-to-Call Volume

Most options investors, including buyers and sellers of GlaxoSmithKline PLC's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. GlaxoSmithKline PLC's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.

Rule 16 of the current GlaxoSmithKline contract

Base on the Rule 16, the options market is currently suggesting that GlaxoSmithKline PLC ADR will have an average daily up or down price movement of about 0.0225% per day over the life of the 2025-05-16 option contract. With GlaxoSmithKline PLC trading at USD 36.38, that is roughly USD 0.008186. If you think that the market is fully incorporating GlaxoSmithKline PLC's daily price movement you should consider buying GlaxoSmithKline PLC ADR options at the current volatility level of 0.36%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
  
Purchasing GlaxoSmithKline PLC options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" GlaxoSmithKline calls. Remember, the seller must deliver GlaxoSmithKline PLC ADR stock to the call owner when a call is exercised.

GlaxoSmithKline PLC Option Chain

When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
GlaxoSmithKline PLC's option chain is a display of a range of information that helps investors for ways to trade options on GlaxoSmithKline. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for GlaxoSmithKline. It also shows strike prices and maturity days for a GlaxoSmithKline PLC against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone.
Open IntStrike PriceCurrent SpreadLast Price
Call
GSK250516C00020000220.015.1 - 18.016.2In
Call
GSK250516C000250002725.011.3 - 11.612.8In
Call
GSK250516C0003000074630.06.5 - 6.66.62In
Call
GSK250516C00035000381335.02.35 - 3.42.89In
Call
GSK250516C00036000376536.01.75 - 2.652.15In
Call
GSK250516C00037000204437.01.25 - 1.351.45Out
Call
GSK250516C00038000120938.00.85 - 1.01.0Out
Call
GSK250516C0003900071039.00.55 - 0.650.6Out
Call
GSK250516C00040000621240.00.35 - 0.450.4Out
Call
GSK250516C00041000217841.00.15 - 0.350.35Out
Call
GSK250516C00042000101442.00.15 - 0.250.36Out
Call
GSK250516C00043000108743.00.1 - 0.20.25Out
Call
GSK250516C0004400016144.00.05 - 0.150.12Out
Call
GSK250516C0004500017345.00.05 - 0.150.05Out
Call
GSK250516C000460001846.00.0 - 0.150.05Out
Call
GSK250516C00047000247.00.0 - 0.350.23Out
Call
GSK250516C00048000448.00.0 - 0.350.19Out
Call
GSK250516C000490001249.00.0 - 0.750.14Out
Call
GSK250516C0005000012650.00.0 - 0.10.1Out
Call
GSK250516C00055000055.00.0 - 0.750.75Out
Call
GSK250516C000600004060.00.0 - 0.10.05Out
 Put
GSK250516P00020000120.00.0 - 1.10.2Out
 Put
GSK250516P000250005225.00.05 - 0.10.02Out
 Put
GSK250516P00030000277330.00.15 - 0.30.2Out
 Put
GSK250516P0003500053235.01.1 - 1.21.05Out
 Put
GSK250516P0003600024036.01.5 - 1.61.25Out
 Put
GSK250516P0003700037337.02.0 - 2.152.1In
 Put
GSK250516P0003800049138.02.4 - 2.82.75In
 Put
GSK250516P0003900020839.03.3 - 5.13.32In
 Put
GSK250516P0004000010040.04.1 - 4.43.9In
 Put
GSK250516P000410007341.03.6 - 6.54.7In
 Put
GSK250516P000420007942.04.0 - 6.38.5In
 Put
GSK250516P0004300012243.05.7 - 7.38.52In
 Put
GSK250516P000440003644.07.5 - 9.66.5In
 Put
GSK250516P00045000045.06.9 - 10.27.5In
 Put
GSK250516P00046000046.09.0 - 11.07.3In
 Put
GSK250516P00047000047.09.7 - 12.99.7In
 Put
GSK250516P00048000048.010.5 - 13.28.4In
 Put
GSK250516P00049000049.010.8 - 14.810.4In
 Put
GSK250516P00050000050.012.2 - 15.012.3In
 Put
GSK250516P00055000055.016.5 - 20.716.5In
 Put
GSK250516P00060000060.022.5 - 25.622.3In

GlaxoSmithKline PLC Market Cap Over Time

   Market Cap   
       Timeline  

GlaxoSmithKline Total Stockholder Equity

Total Stockholder Equity

16.12 Billion

At this time, GlaxoSmithKline PLC's Total Stockholder Equity is quite stable compared to the past year.

GlaxoSmithKline PLC Corporate Directors

Lynn ElsenhansIndependent Non-Executive DirectorProfile
Harry DietzNon-Executive Independent Director, Scientific and Medical ExpertProfile
Charles BancroftNon-Executive Independent DirectorProfile
Vivienne CoxIndependent Non-Executive Director and Workforce Engagement DirectorProfile
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.28)
Earnings Share
1.55
Revenue Per Share
15.38
Quarterly Revenue Growth
(0.02)
Return On Assets
0.0724
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.